Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

This article is part of the supplement: Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference

Open Access Open Badges Proceedings

ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective

Katya Tsaioun1*, Michel Bottlaender2, Aloise Mabondzo3 and the Alzheimer's Drug Discovery Foundation

Author affiliations

1 Apredica, 313 Pleasant Street, Watertown, MA 02472, USA

2 CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, 91401, France

3 CEA, iBiTec-S, Service de Pharmacologie et d'ImmunoAnalyse, Gif-sur-Yvette, 91191, France

For all author emails, please log on.

Citation and License

BMC Neurology 2009, 9(Suppl 1):S1  doi:10.1186/1471-2377-9-S1-S1

Published: 12 June 2009


The advent of early absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening has increased the attrition rate of weak drug candidates early in the drug-discovery process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons. This paper reviews the history of ADMET screening and its place in pharmaceutical development, and central nervous system drug discovery in particular. Assays that have been developed in response to specific needs and improvements in technology that result in higher throughput and greater accuracy of prediction of human mechanisms of absorption and toxicity are discussed. The paper concludes with the authors' forecast of new models that will better predict human efficacy and toxicity.